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Abstract Although copy number variations (CNVs) are
expected to affect various diseases, little is known about
the association between CNVs and breast cancer suscepti-
bility. Therefore, we investigated this relation. Array com-
parative genomic hybridization was performed to search for
candidate CNVs related to breast cancer susceptibility. Sub-
sequent quantitative real-time polymerase chain reaction
was carried out for confirmation. We found seven CNV
markers associated with breast cancer risk. The means of
the relative copy numbers of patients with a history of breast
cancer and women in the control group were 0.8 and 1.8 for
Hs06535529_cn on 1p36.12 (P<0.0001), 2.9 and 2.2 for
Hs03103056_cn on 3q26.1 (P<0.0001), 1.2 and 1.8 for
Hs03899300_cn on 15q26.3 (P<0.0001), 1.0 and 1.5 for
Hs03908783_cn on 15q26.3 (P<0.0001), and 1.1 and 1.7
for Hs03898338_cn on 15q26.3 (P<0.0001), respectively.
Interestingly, nine or more copies of Hs04093415_cn on
22q12.3 were found only in 8/193 (4.1 %) patients with a
history of breast cancer and in none of the controls (P=
0.0081). Similarly, 12 or more copies of Hs040908898_cn
on 22q12.3 were found only in 7/193 (3.6 %) patients with a
history of breast cancer and in none of the controls (P=
0.016). A combination of two CNVs resulted in 80.3 %
sensitivity, 80.6 % specificity, 82.4 % positive predictive
value, and 78.3 % negative predictive value for the predic-
tion of breast cancer susceptibility. These findings may lead
to a new means of risk assessment for breast cancer. Con-
firmatory studies using independent data sets are needed to
support our findings.
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Introduction
Breast cancer is a multifactorial disease caused by genetic
and environmental factors [1]. So far, genetic studies have
identified four high-penetrance genes (BRCA1, BRCA2,
TP53, and PTEN) related to breast cancer [2]. In addition,
genetic variations including single-nucleotide polymor-
phisms (SNPs), small insertion–deletion polymorphisms,
and variable numbers of repetitive sequences have been
reportedly associated with breast cancer risk, comprising
51 variants in 40 genes graded as a strong relation for 10
variants in 6 genes (ATM, CASP8, CHEK2, CTL4, NBN, and
TP53), moderate for 4 variants for 4 genes (ATM, CYP19A1,
TERT, and XRCC3), and weak for 37 variants [3].
Another variation in the human genome is that of genomic
structural variants including copy number variations (CNVs)
[4]. The CNVs involve gains or losses of several to hundreds
of kilobases of genomic DNA among phenotypically normal
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individuals, and at least 11,700 CNV regions larger than
443 bp have been identified [5]. CNVs have been shown to
significantly influence messenger RNA expression levels [6,
7], and recent studies have described associations of CNVs
with various common disorders [8] as well as with mental
illness [9]. As examples, The Wellcome Trust Case Control
Consortium identified three CNVs associated with common
diseases: IRGM for Crohn’s disease;HLA for Crohn’s disease,
rheumatoid arthritis, and type 1 diabetes; and TSPAN8 for type
2 diabetes [10]. In regard to neoplasms, CNVs have recently
been reported as factors predisposing individuals to neuro-
blastoma, prostate cancer, pancreatic cancer, colorectal cancer,
and BRCA1-associated ovarian cancer [6, 11–15]. Although
CNVs are expected to affect breast cancer risk, little is known
about this association except for a previous report in which the
proportion of rare CNVs was excessive in patients with he-
reditary breast cancer without BRCA1/BRCA2mutations com-
pared with controls [16]. These gaps, in our knowledge,
prompted us to study this relation. Here, we report that CNVs
significantly affect the susceptibility to breast cancer.
Materials and methods
The study protocol was approved by the institutional review
board of Yamaguchi University Graduate School of Medi-
cine, and informed consent was obtained from each patient.
Screening of CNVs by array comparative genomic
hybridization
We obtained 30 DNA samples from the peripheral blood of
women without a history of breast cancer and 30 DNA
samples from the peripheral blood of patients with a history
of breast cancer. A pool of blood-derived DNA from the 30
healthy women was used as a reference sample for all
hybridizations performed. Assessment of the CNVs in the
human genome by oligonucleotide array comparative ge-
nomic hybridization (CGH) (human CGH 2.1 M whole-
genome tiling array; Roche NimbleGen) was performed
according to the manufacturer’s protocol. Array image anal-
ysis and normalization were performed with NimbleScan
version 2.5 software (Roche NimbleGen). The normalized
data were then processed using Nexus Copy Number ver-
sion 5.0 software (BioDiscovery).
Copy number validation by real-time polymerase chain
reaction
Quantitative real-time polymerase chain reaction (PCR) us-
ing predesigned TaqMan® Copy Number Assays (Applied
Biosystems) containing a primer pair and a FAM dye-
labeled minor groove binder (MGB) probe was performed
to detect the copy number of the genomic sequence of
interest using a larger cohort. For the internal control, a
predesigned TaqMan® Copy Number Reference Assay RN-
ase P (Applied Biosystems), which is known to exist in two
copies in a diploid genome, was used. We obtained 193
DNA samples from the peripheral blood of patients with a
history of breast cancer and 170 DNA samples from age-
matched women without a history of breast cancer. The
mean age was 57.3 years in the patient group and 55.6 years
in the control group. There was no statistical difference in
age distribution between the groups. The calibrator sample
for quantitative real-time PCR was the DNA pooled from 30
healthy women; the same was used as the reference in the
array CGH assay, and the copy number of the calibrator
sample was assumed to be 2. The 7900HT system and the
StepOnePlus system (Applied Biosystems) were used for
the quantitative real-time PCR analysis. The PCRs were
carried out according to the manufacturer’s protocol.
TA cloning
To confirm the DNA sequence, a part of the real-time PCR
products were gel purified and cloned into the T/A cloning
vector pGEM-T Easy (Promega). At least five subclones
were isolated and identified by direct sequencing.
Copy number validation by digital PCR
Digital PCR was available for six CNVs including
Hs06535529_cn, Hs03899300_cn, Hs03908783_cn,
Hs03898338_cn, Hs04090898_cn, and Hs040904315_cn to
evaluate absolute copy numbers. Regarding Hs03103056_cn,
digital PCR was not available because of difficulties in design-
ing primers and probes for digital PCR. To evaluate the copy
number of Hs03899300_cn, we designed forward and reverse
primers and a TaqMan® MGB probe of Hs03899300_cn re-
gion and hTERT. hTERT was used as the internal control
because it is known to exist in two copies in a diploid genome
[17]. The primers were 5′-TGCCTGGCACTAAGGTTTA
GAGTT-3′ (forward) and 5′-CACTCAGAGGGTTAAGT
GAAGTGACA-3′ (reverse) for the Hs03899300_cn region
and 5′-GGGTCCTCGCCTGTGTACAG-3′ (forward) and 5′-
CCTGGGAGCTCTGGGAATTT-3′ (reverse) for hTERT. The
probes were 5′-FAM-TGAGTCGGTGCTTCC-MGB-3′ for
the Hs03899300_cn region and 5′-VIC-CACACCTTTGGT
CACTC-MGB-3′ for hTERT. We designed these primers and
probes to avoid SNPs. Regarding other CNVs, the same Copy
Number Assays used in the real-time PCR were available.
Reaction mixtures of 20-μL volume comprising 1× ddPCR
MasterMix (Bio-Rad), forward and reverse primers and probes
for a target and a reference, and DNA were prepared. PCR
amplification was performed for a total of 40 cycles with an
annealing temperature of 58 °C. Digital PCR was carried out
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using a QX100 droplet digital PCR system (BioRad) according
to the manufacturer’s protocol [18].
Statistical analysis
A Fisher’s exact test, an unpaired t test, a Mann–Whitney
test, linear regression analysis, and linear discriminant anal-
ysis were used to compare variables. A P value of <0.05 was
considered to be significant. Data were analyzed with
GraphPad Prism version 4.03, GraphPad InStat version
3.10 (GraphPad Software), and Ekuseru-Toukei 2008 (So-
cial Survey Research Information).
Results
Using array CGH, we found four CNV regions with significant
differences in the frequency of copy number changes between
the patient group and the control group. The CNV positions
were chr1:21,500,972-21,505,481; chr3:162,215,705-
162,235,598; chr15:102,029,706-102,034,387; and
chr22:37,142,958-37,147,755 (GRCh37/hg19). The CNVs
detected by array CGH, however, could be false positives
because a poor signal-to-noise ratio of hybridizations leads to
considerable variation in the reported CGH ratio [19], and
smaller CNVs are much more likely to be false positives than
are large CNVs [20]. Therefore, quantitative real-time PCR
with a larger cohort was carried out to confirm the CNVs
associatedwith breast cancer susceptibility.We identified seven
CNVmarkers related to breast cancer risk as shown in Table 1.
The means of the relative copy numbers of patients with a
history of breast cancer and those of women in the control
group were 0.8 and 1.8 for Hs06535529_cn on 1p36.12 (P<
0.0001), 2.9 and 2.2 for Hs03103056_cn on 3q26.1 (P<
0.0001), 1.2 and 1.8 for Hs03899300_cn on 15q26.3 (P<
0.0001), 1.0 and 1.5 for Hs03908783_cn on 15q26.3 (P<
0.0001), and 1.1 and 1.7 for Hs03898338_cn on 15q26.3 (P
<0.0001), respectively (Fig. 1). The copy number of the
Hs03899300_cn region on 15q26.3 by digital PCR was con-
sistent with that by real-time PCR (Fig. 2), and the decision
coefficient (r2) was 0.9801. Also, copy numbers of other CNVs
by digital PCR and by real-time PCR were well correlated: r2
was 0.9201 for Hs06535529_cn, 0.8450 for Hs03908783_cn,
0.8909 for Hs03898338_cn, 0.9958 for Hs04090898_cn, and
0.9491 for Hs04093415_cn. Interestingly, nine or more copies
of Hs04093415_cn on 22q12.3 were found only in eight
(4.1 %) patients with a history of breast cancer and in none of
the controls (P=0.0081, Fig. 1 and Table 2). Similarly, 12 or
more copies of Hs04090898_cn on 22q12.3 were found only in
7 (3.6 %) patients with a history of breast cancer and in none of
the controls (P=0.0160, Fig. 1 and Table 2). After setting a copy
number threshold, we evaluated the relation between the copy
number events and breast cancer susceptibility. The sensitivity
and specificity were 83.9 and 41.2 % for Hs06535529_cn, 39.4
and 90.0 % for Hs03103056_cn, 76.7 and 70.0 % for
Hs03899300_cn, 79.8 and 45.3 % for Hs03908783_cn, 83.4
and 65.9 % for Hs03898338_cn, 4.1 and 100.0 % for
Hs04093415_cn, and 3.6 and 100.0 % for Hs04090898_cn
(Table 2). Linear discriminant analysis with combination of
two CNVs resulted in 80.3 % sensitivity, 80.6 % specificity,
82.4% positive predictive value, and 78.3% negative predictive
value for the prediction of breast cancer susceptibility. The
discriminant score was calculated as follows: Y=−6.9X1+
3.2X2+6.1, where X1=the copy number of Hs03899300_cn
and X2=the copy number of Hs03908783_cn.
Discussion
In the current study, we identified CNV loci associated with
breast cancer susceptibility. Our results, however, contrast
with the study of Craddock et al. [10], who reported that there
was no association between CNVs and breast cancer risk. This
discrepancy is likely caused by the differences in the array-
CGH platforms and analytic tools used. Different calling
algorithms in the analytic tools give substantially a different
quantity and quality of CNV calls even when identical raw
data are used as the input [21]. Differences in preprocessing,
labeling, and hybridization protocols, which were performed
according to the various manufacturers’ specifications, could
contribute to the occurrence of false-negative and false-
positive calls [22]. Therefore, comparison of data sets result-
ing from different platforms and/or different analytic tools will
cause problems in association analysis and can create false
association signals [21]. To evaluate a copy number exactly, it
is necessary to follow a validation study using a different
methodology such as that of real-time PCR [22].
In the current study, we found that the copy numbers of
Hs03899300_cn, Hs03908783_cn, and Hs03898338_cn, which
are located close to each other on 15q26.3, were similar by real-
time PCR. These findings were also observed between
Hs04093415_cn and Hs040908898_cn on 22q12.3. Further-
more, the copy number of six CNVs includingHs06535529_cn,
Hs03899300_cn, Hs03908783_cn, Hs03898338_cn,
Hs04090898_cn, and Hs040904315_cn evaluated by digital
PCR confirmed the accuracy of the data from the real-time
PCR. Thus, false positives and negatives from the real-time
PCR could be excluded. To our knowledge, this is the first
report to show a distinct relation between CNVs and breast
cancer risk.
Interestingly, 9 or more copies of Hs04093415_cn and 12
or more copies of Hs040908898 were observed only in
patients with a history of breast cancer, and odds ratios for
breast cancer susceptibility were 19.8 and 17.4, respectively.
Such high odds ratios suggest strong oncogenic effect in
these regions. Because mutations of high-penetrance genes
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for breast cancer (BRCA1, BRCA2, TP53, and PTEN) have
not been tested, and familial history was not available in the
present study, further studies are required to elucidate the
association of the CNVs and hereditary breast cancer
syndromes.
In the current study, some of the CNV regions related to
breast cancer susceptibility contained genes such as EIF4G3
and PCSK6. Eukaryotic initiation factor 4 gamma 3
(EIF4G3) is a protein critical for initiation of protein trans-
lation [23]. To date, no relation of EIF4G3 with cancer
development has been reported. We hypothesize that the
decrease in the germline copy number of EIF4G3 may lead
to a reduction or failure in translation of some transcripts
and possibly give malignant potential to cells. Further ex-
amination will be required to elucidate this speculation.
Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a
member of the protease family of proprotein convertases
that activate precursor proteins by cleaving at the specific
recognition sequence RXK/RR [24]. The relation between
PCSK6 expression and carcinogenesis is controversial.
Some investigations reported that overexpression of PCSK6
in immortalized nontumorigenic or papilloma-derived kera-
tinocytes increased their invasiveness [25], whereas other
studies linked absent or reduced PCSK6 expression levels to
ovarian cancer [26]. Regarding breast cancer, overexpres-
sion of prosegment ppPCSK6 resulted in significant en-
hancement in cell motility, migration, and invasion of
collagen in vitro [27]. However, because the effect of the
reduced copy number of PCSK6 on normal mammary gland
cells has not yet been investigated, further examination will
be required to understand the function of PCSK6 in the
neoplastic process.
The fact that no genes were mapped to the rest of the CNV
regions raises a question as to how such CNVs affect breast
cancer development. A possible explanation is that new gene
transcripts may exist within the CNVs. Indeed, Diskin et al.
Table 1 CNV markers related to breast cancer risk
Copy number assay
ID
Sequence Location Gene Copy number variation ID
(GRCh37/hg19) (Database of genomic variants)
Hs06535529_cn TCGCTGTGCCTGATTTCAGAGCCGGTTTCT chr1:21,502,843 EIF4G3 None
GCGGTAAACTCATGGCAAAGCGAAGCCAC −21,502,924
CAACCCCCCCAGAGCGGGACCGG
Hs03103056_cn TGGCAACATCTCAATATCCRCAGAATTTTC chr3:162,223,478 None 2483, 62120, 103483, 115882,
ATATTTATCCAGGTAGAATTGATAAACAGA −162,223,593 32527, 37991, 30185, 50989, 2483,
AAATTCCACAAGAACCATAAATTATTTAAC 62120, 103483, 115882, 32527,
ACATACACACACACACTCAAATTTAG 37991, 30185, 50989








Hs03898338_cn ATCGCTGCTGGATCTCTTCTGTCATCCCTCC chr15:102,031,024 None 34506, 5327, 3984
CAGGACCCATTGGTCCTACTGGCCCACTTC −102,031,100
CAGAAAGCAAGCCATC
Hs04093415_cn GTGTCGAGGCTGCTCCTTAAAYGCTTCTTG chr22:37,143,784 None 36022, 36023, 7346, 110470, 36024,
CCTGCACGCTGTGCGTGGAAACCCAAAGA −37,143,858 22687, 103172, 23103, 115199,
AGTGAGAGACGCGAGG 62002, 6148, 115197, 59075, 79571,
22687, 103172, 23103, 115199,
62002, 6148, 115197, 59075, 79571,
110470, 36024, 36022, 36023, 7346
Hs04090898_cn CTCCTAGTGGGATCCTACAACTCTCAGAAC chr22:37,145,991 None 36022, 36023, 36024, 22687, 103172,
AACAGGGTCCCCCTGGACTGTGAGCACAGT −37,146,097 23103, 62002, 6148, 115197, 59075,
AGAACCAGCTCTTTCTTGGGATTTTAAGAA 91054, 7347, 79570, 91053, 36022,
AACAGACAAGCTTCGCG 36023, 36024, 22687, 103172,
23103, 62002, 6148, 115197, 59075,
91054, 7347, 79570, 91053
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found a new gene transcript related to neuroblastoma within
the 1q21.1 CNV region where no known genes had been
Hs06535529_cn









































































































































Fig. 1 Distribution of copy
numbers in patients with a
history of breast cancer and in
women in the control group.
Each sample is indicated by an
open circle. The horizontal
lines represent the mean copy






















Fig. 2 Comparison of Hs03899300_cn copy number between real-time
PCR and digital PCR evaluation. Dark and light gray bars represent the
copy numbers evaluated by real-time PCR and by digital PCR, respectively











(n=193, %) (n=170, %)
Hs06535529_cn <1.5 162 (83.9) 100 (58.8) 3.7 <0.0001
Hs03103056_cn 3.5≤ 76 (39.4) 17 (10.0) 5.8 <0.0001
Hs03899300_cn <1.5 148 (76.7) 51 (30.0) 7.7 <0.0001
Hs03908783_cn <1.5 154 (79.8) 93 (54.7) 3.3 <0.0001
Hs03898338_cn <1.5 161 (83.4) 58 (34.1) 9.7 <0.0001
Hs04093415_cn 9.0≤ 8 (4.1) 0 (0.0) 15.6 0.0081
Hs04090898_cn 12.0≤ 7 (3.6) 0 (0.0) 13.7 0.0160
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mapped [6]. Another hypothesis is that noncoding RNAs may
be involved, such as long intergenic noncoding RNAs that
regulate chromatin states and epigenetic inheritance, but
knowledge of the molecular mechanisms of their function
are still lacking [28]. Because the function of the CNVs is still
unknown, further examinations will be required.
In summary, we found several unique CNVs associated
with breast cancer. These CNVs may be feasible markers for
assessment of the risk of breast cancer. However, as we
cannot exclude the possibility that some women without a
history of breast cancer may develop breast cancer in the
future because the lifetime risk of developing breast cancer
in Japan is 6 % [29], confirmatory studies using independent
data sets are needed to support our findings.
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